Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Cibinqo Atopic Dermatitis Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Cibinqo (abrocitinib) Coverage Criteria for Atopic Dermatitis

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA prior authorization and reauthorization for Cibinqo in members 12 years of age and older with refractory, moderate-to-severe atopic dermatitis. It defines required documentation, prescriber qualifications, clinical criteria, safety requirements, and authorization durations.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyCibinqo (abrocitinib) Coverage Criteria for Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit the HMSA prior authorization fax form with documentation of clinical criteria, prior treatment history, and required safety screening.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+Minimum member age
    4 monthsInitial authorization
    12 monthsReauthorization
    10% BSADisease involvement threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    180 daysPrior systemic therapy lookback
    12 monthsTB testing interval

    Coverage Criteria

    Initial Therapy Criteria

    Covered when the member is 12 years of age or older and meets at least one of the following initial-therapy pathways:

    Initial therapy pathways

    • Prior biologic or systemic targeted synthetic drug pathway: The member previously received a biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis.within the past 180 days

      Examples include Dupixent, Ebglyss, or Rinvoq.

    • Disease severity and treatment history pathway

      • Disease involvement: Affected body surface is greater than or equal to 10%, or crucial body areas are affected.>= 10% body surface area or crucial body areas

        Crucial areas include the hands, feet, face, neck, scalp, genitals/groin, and intertriginous areas.

      • Topical therapy history or inadvisability

        • Inadequate response to topical therapies

          • Topical corticosteroid: Inadequate response to a high-potency or super-high-potency topical corticosteroid.2 consecutive weeks
          • Topical calcineurin inhibitor: Inadequate response to a topical calcineurin inhibitor, specifically tacrolimus.6 consecutive weeks
          • Topical JAK inhibitor: Inadequate response to a topical JAK inhibitor, specifically Opzelura.8 consecutive weeks
      • Other systemic therapy response: The member had an inadequate response, intolerance, or contraindication to another systemic drug product, including a biologic, indicated for atopic dermatitis.within the past 180 days

        Examples include Adbry, Rinvoq, Dupixent, Ebglyss, or Nemluvio.

    Continuation and Reauthorization Criteria

    Continuation coverage requires the applicable pathway below:

    Continuation pathways

    • No previous authorization or precertification: All members, including new members and members currently receiving treatment without prior authorization, meet the initial-therapy criteria.
    • Reauthorization after prior HMSA/CVS authorization: The member was previously authorized by HMSA/CVS and achieved or maintained a positive clinical response since starting Cibinqo.12-month authorization

      Positive clinical response is evidenced by low disease activity, such as clear or almost clear skin, or improvement in atopic dermatitis signs and symptoms such as redness, itching, or oozing/crusting.

    Cibinqo is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

    Cibinqo must not be administered to a member with active tuberculosis (TB) infection.

    Cibinqo cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Initial Therapy Criteria

    Initial Authorization

    Authorization of 4 months may be granted when the member is 12 years of age or older and meets at least one of the following initial-therapy pathways:

    Initial authorization pathways

    • Prior biologic or systemic targeted synthetic drug pathway: The member previously received a biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis.within the past 180 days

      Examples include Dupixent, Ebglyss, or Rinvoq.

    • Disease severity and treatment history pathway

      • Disease involvement: Affected body surface is greater than or equal to 10%, or crucial body areas are affected.>= 10% body surface area or crucial body areas

    Continuation and Reauthorization Criteria

    Continuation and Reauthorization

    Continuation and reauthorization are covered under the applicable pathway below:

    Continuation requirements

    • No previous authorization or precertification: All members, including new members and members currently receiving treatment without prior authorization, meet the initial-therapy criteria in the initial approval section.
    • Reauthorization after prior HMSA/CVS authorization: The member was previously authorized by HMSA/CVS and achieved or maintained a positive clinical response since starting Cibinqo.12-month authorization

      Positive clinical response is evidenced by low disease activity, such as clear or almost clear skin, or improvement in atopic dermatitis signs and symptoms such as redness, itching, or oozing/crusting.

    Clinical Thresholds and Treatment History

    Affected body surface area
    Standard thresholdAffected body surface area must be greater than or equal to 10%.
    ExceptionThe 10% threshold does not apply when crucial body areas are affected.
    Coverage contextThe disease-involvement requirement applies to members receiving treatment for moderate-to-severe atopic dermatitis.
    Topical corticosteroid trial
    TherapyHigh-potency or super-high-potency topical corticosteroid.
    Required trial2 consecutive weeks.
    Response requirement

    Provider Requirements and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Cibinqo can be covered. Submit the request using the HMSA fax form available on the HMSA medical policy website.

    • Refer to the HMSA medical policy website for the required fax form.
    Billing Rule

    Qualified Prescriber Required

    Cibinqo must be prescribed by, or prescribed in consultation with, a qualified specialist.

    • Required prescriber or consultant: dermatologist or allergist/immunologist.

    Drug and Indication Background

    Cibinqo (abrocitinib) is indicated for adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

    Policy Definitions

    Crucial body areas
    Hands and feetHands and feet are considered crucial body areas.
    Head and neckFace, neck, and scalp are considered crucial body areas.
    Other areasGenitals/groin and intertriginous areas are considered crucial body areas.
    Positive clinical response
    Skin statusClear or almost clear skin.
    Signs and symptomsImprovement in atopic dermatitis signs and symptoms.
    Examples of improvementReduced redness, itching, or oozing/crusting.

    Step Therapy Requirements

    StepRequired prior therapyTimingPathway exception
    1A biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis, such as Dupixent, Ebglyss, or Rinvoq.Received within the past 180 days.This pathway is an alternative to the full topical-therapy sequence in Step 2.
    StepRequired topical therapiesRequired trial durationAlternative to treatment trials
    2High- or super-high-potency topical corticosteroid; topical calcineurin inhibitor (tacrolimus); topical JAK inhibitor (Opzelura); and topical aryl hydrocarbon receptor agonist (Vtama).Within the past 365 days: corticosteroid for 2 consecutive weeks; calcineurin inhibitor for 6 consecutive weeks; topical JAK inhibitor for 8 consecutive weeks; and aryl hydrocarbon receptor agonist for 8 consecutive weeks.The specified topical therapies need not be tried when their use is not advisable, such as because of a contraindication, prior intolerance, age-inappropriate potency, or other clinical reason.

    Quantity Limits

    Cibinqo dosing limits
    ProductCibinqo (abrocitinib).
    Dosing basisFDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.
    Quantity-limit ruleApprovals may be subject to dosing limits; an exact quantity is not specified in the policy.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyCibinqo (abrocitinib) Coverage Criteria for Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit the HMSA prior authorization fax form with documentation of clinical criteria, prior treatment history, and required safety screening.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Reauthorization CriteriaClinical Thresholds and Treatment HistoryProvider Requirements and Coverage RisksDrug and Indication BackgroundPolicy DefinitionsStep Therapy RequirementsQuantity Limits
    Topical aryl hydrocarbon receptor agonist: Inadequate response to a topical aryl hydrocarbon receptor agonist, specifically Vtama.8 consecutive weeks
  1. Topical therapies not advisable: Use of the high-potency or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical aryl hydrocarbon receptor agonist was not advisable for the member.

    Examples include contraindications, prior intolerances, potency not appropriate for the member's age, or inadequate response.

  2. Crucial areas include the hands, feet, face, neck, scalp, genitals/groin, and intertriginous areas.

  3. Topical therapy history or inadvisability

    • Inadequate response to topical therapies

      • Topical corticosteroid: Inadequate response to a high-potency or super-high-potency topical corticosteroid.2 consecutive weeks
      • Topical calcineurin inhibitor: Inadequate response to a topical calcineurin inhibitor, specifically tacrolimus.6 consecutive weeks
      • Topical JAK inhibitor: Inadequate response to a topical JAK inhibitor, specifically Opzelura.8 consecutive weeks
      • Topical aryl hydrocarbon receptor agonist: Inadequate response to a topical aryl hydrocarbon receptor agonist, specifically Vtama.8 consecutive weeks
    • Topical therapies not advisable: Use of the high-potency or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical aryl hydrocarbon receptor agonist was not advisable for the member.

      Examples include contraindications, prior intolerances, potency not appropriate for the member's age, or inadequate response.

  4. Other systemic therapy response: The member had an inadequate response, intolerance, or contraindication to another systemic drug product, including a biologic, indicated for atopic dermatitis.within the past 180 days

    Examples include Adbry, Rinvoq, Dupixent, Ebglyss, or Nemluvio.

  5. The member must have an inadequate treatment response.
    Topical calcineurin inhibitor trial
    TherapyTopical calcineurin inhibitor, specifically tacrolimus.
    Required trial6 consecutive weeks.
    Response requirementThe member must have an inadequate treatment response.
    Topical JAK inhibitor trial
    TherapyTopical JAK inhibitor, specifically Opzelura.
    Required trial8 consecutive weeks.
    Response requirementThe member must have an inadequate treatment response.
    Topical aryl hydrocarbon receptor agonist trial
    TherapyTopical aryl hydrocarbon receptor agonist, specifically Vtama.
    Required trial8 consecutive weeks.
    Response requirementThe member must have an inadequate treatment response.
    Prior systemic therapy
    Qualifying therapyA biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis.
    Lookback periodThe therapy must have been received within the past 180 days.
    ExamplesExamples include Dupixent, Ebglyss, and Rinvoq.
    Tuberculosis testing
    Required resultA documented negative tuberculosis test.
    TimingWithin 12 months of initiating therapy.
    Applicable membersPersons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB.
    Step Therapy

    Prior Topical and Systemic Therapy

    Document the required prior topical and systemic therapy history before requesting initial authorization. Treatment must have produced an inadequate response, been intolerable, or been contraindicated/not advisable as specified by the policy.

    • Within the past 365 days, document inadequate response to all of the following unless their use is not advisable: high- or super-high-potency topical corticosteroid for 2 consecutive weeks; topical calcineurin inhibitor (tacrolimus) for 6 consecutive weeks; topical JAK inhibitor (Opzelura) for 8 consecutive weeks; and topical aryl hydrocarbon receptor agonist (Vtama) for 8 consecutive weeks.
    • Document an inadequate response, intolerance, or contraindication to another systemic atopic dermatitis therapy, including a biologic or targeted synthetic drug, within the past 180 days.
    • The topical therapies may instead be omitted when documentation shows they are not advisable, such as because of contraindication, prior intolerance, age-inappropriate potency, or inadequate response.
    • A member who received a biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis within the past 180 days may qualify for a 4-month authorization.
    Documentation Required

    Initial Request Documentation

    For an initial request, submit chart notes or medical records documenting the clinical presentation and treatment history needed for review.

    • Show the affected area(s) and affected body surface area, where applicable.
    • Document previous medications tried, including topical corticosteroids, topical calcineurin inhibitors, topical JAK inhibitors, topical aryl hydrocarbon receptor agonists, and biologics or targeted synthetic drugs.
    • For each prior therapy, include dosage, duration, and response to treatment.
    • If a therapy was not advisable, document the applicable clinical reason, such as a contraindication or intolerance.
    Documentation Required

    Continuation Documentation

    For continuation or reauthorization requests, provide current clinical documentation showing that the member achieved or maintains a positive response to Cibinqo.

    • Submit chart notes or medical record documentation supporting the positive clinical response.
    • Examples include low disease activity with clear or almost clear skin, or improvement in redness, itching, or oozing/crusting.

    Unsupported block type: documentation

    Denial Risk

    Prohibited Concomitant Therapy or Active TB

    Do not use Cibinqo with prohibited concomitant therapies, and do not administer it to a member with active TB infection.

    • Cibinqo is not recommended or permitted concomitantly with another JAK inhibitor, biologic immunomodulator, other immunosuppressant, or another biologic or targeted synthetic drug for the same indication.
    • Do not administer Cibinqo to members with active TB infection.
    • Resolve prohibited concomitant therapy and active TB concerns before initiation.
    Denial Risk

    Initial Clinical Criteria Not Met

    Initial coverage may be denied when the member does not satisfy the age, disease-severity, prior-treatment, or clinical-response requirements.

    • Member must be at least 12 years of age.
    • Disease must be moderate to severe, with affected body surface area of at least 10% or involvement of crucial areas such as the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.
    • Required topical therapies must show inadequate response, or documentation must establish that their use is not advisable.
    • Another systemic atopic dermatitis therapy, including a biologic, must have resulted in inadequate response, intolerance, or contraindication within the past 180 days, unless the applicable policy pathway is otherwise satisfied.
    • Missing documentation of prior treatment, inadequate response, intolerance, or contraindication creates coverage risk.
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied without evidence that the member achieved or maintained a positive clinical response since starting Cibinqo.

    • Document low disease activity, such as clear or almost clear skin, or improvement in atopic dermatitis signs and symptoms.
    • Relevant improvements may include reduced redness, itching, or oozing/crusting.
    • Reauthorization is for 12 months when the member was previously authorized by HMSA/CVS and the required response is demonstrated.
    Denial Risk

    Prescriber Specialty Requirement

    Coverage is at risk when the medication is prescribed without the required specialist involvement.

    • The prescriber must be a dermatologist or allergist/immunologist, or the medication must be prescribed in consultation with one.
    • Include evidence of the qualified prescriber or consultation in the authorization documentation.
    Latent TB
    DefinitionTuberculosis infection without active disease.
    Required evaluationIf TB screening is positive, further testing must confirm that there is no active disease.
    Before CibinqoTB treatment must be started before Cibinqo initiation.
    Topical corticosteroid potency groups
    OrganizationThe appendix organizes topical corticosteroids into potency groups I through VII.
    Entry detailsEach entry specifies the drug, dosage form, and strength.
    Groups shown in cited appendix excerptsThe cited appendix excerpts include group 5 (lower-mid potency), group 6 (low potency), and group 7 (least potent).